文献速递泌尿生殖与妇科肿瘤放疗

FLAME试验中接受局灶推量放疗后前列腺内复发:复发位置与剂量分布分析

Intra-prostatic recurrences after radiotherapy with focal boost: Location and dose mapping in the FLAME trial.
PubMed 文献 · Radiother Oncol · 2024-09-13

FLAME试验显示GTV剂量与肿瘤控制相关,引发对剩余前列腺腺体是否可降低剂量的思考。本研究分析FLAME试验中535例患者里28例前列腺内复发者,对24例可定位者的治疗前影像、GTV勾画和剂量分布与复发后PSMA-PET CT进行配准。结果显示复发主要位于原发肿瘤GTV位置,除1例外所有复发患者GTV的D98%均低于81 Gy。

要点

  • FLAME试验535例中28例发生前列腺内复发,24例可定位复发位置。
  • 仅1例复发位于GTV外的前列腺腺体,其余均位于GTV内。
  • 复发患者GTV的D98%中位值为76.5 Gy(范围73.3-86.5 Gy),除1例外均低于81 Gy。

核心结论

  • 中高危前列腺癌患者接受放疗后,前列腺内复发主要出现在原发肿瘤位置。
  • 除1例外,复发患者均未接受GTV高剂量照射,前列腺内失败更可能是原发肿瘤治疗不足而非剩余前列腺腺体治疗不足所致。

研究设计与样本

  • FLAME试验中535例患者里28例发生前列腺内复发,对其中24例可定位者收集治疗前影像、GTV勾画、剂量分布及复发后PSMA-PET CT影像,将治疗前影像与复发后影像配准,GTV与PSMA-PET活性重叠定义为原发肿瘤位置的前列腺内复发。

主要发现

  • 535例中28例发生前列腺内复发,24例可确定复发位置。
  • 1例复发位于GTV外的前列腺腺体,其余复发位于GTV位置。
  • GTV的近最小剂量(D98%)中位值为76.5 Gy(范围73.3-86.5 Gy)。
  • 仅1例GTV内复发患者接受了86.5 Gy的局灶推量,其余所有患者D98%均<81 Gy。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: The FLAME trial demonstrated that the dose to the gross tumor volume (GTV) is associated with tumour control in prostate cancer patients. This raises the question if dose de-escalation to the remaining prostate gland can be considered. Therefore, we investigated if intraprostatic recurrences occur at the location of the GTV and which dose was delivered at that location. MATERIALS AND METHODS: For FLAME trial patients with an intra-prostatic recurrence, we collected pre-treatment images, GTV delineations, dose distributions and post-recurrence images. Pre-treatment images were registered to the post-recurrence images (PSMA-PET CT). An overlap between GTV and PSMA-PET activity was considered an intra-prostatic recurrence at the location of the primary tumor. RESULTS: Twenty eight out of 535 patients in the FLAME trial had an intra-prostatic recurrence. Its location could be determined for 24 patients. One patient recurred in the prostate gland outside the GTV. The median near-minimum dose to the GTV (D98%) was 76.5 Gy (range: 73.3-86.5 Gy). Only one patient with a recurrence in the GTV received a substantial focal boost of 86.5 Gy. The D98% of all remaining patients was < 81 Gy. CONCLUSION: Intra-prostatic recurrences of intermediate- and high-risk prostate cancer patients treated with radiotherapy appeared predominantly at the location of the primary tumor. All but one patient did not receive a high dose to the GTV. Intra-prostatic failure is likely a consequence of the undertreatment of the primary tumor rather than the undertreatment of the remaining prostate gland.

来源:Radiother Oncol,查看原文。版权归原作者所有。

引用

  1. Menne Guricová K, Pos FJ, Schoots IG, et al. Intra-prostatic recurrences after radiotherapy with focal boost: Location and dose mapping in the FLAME trial. Radiother Oncol. 2024. PMID: 39278316. doi:10.1016/j.radonc.2024.110535

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。